Beijing | Shanghai | Shenzhen | Hong Kong | SingaporeCompany Resourceswww.apvaluation.com
APA Consulting & Appraisal

IPO Project Experience

IPO Project Experience

IPO project experience across industries, listing markets and valuation scopes.

No.CompanyIndustryListing InformationValuation Scope
1Londian WasonNew EnergyNYSE, 2026-08Equity valuation
2CrealityTMTHong Kong, 2026-05Share-based payments; property valuation
3LDRobotIndustrialHong Kong, 2026-05Enterprise value; share-based payments
4Haizhi TechnologyTMTHong Kong, 2026-02Fair value measurements
5Ribo Life SciencePharmaceuticalsHong Kong, 2026-01Property valuation
6Iluvatar CoreXTMTHong Kong, 2026-01Long-term equity investments; share-based payments
7Zhipu AITMTHong Kong, 2026-01Purchase price allocation; goodwill impairment testing; share-based payments
851WORLDTMTHong Kong, 2025-12Financial assets; preferred shares
9Guoxia TechnologyTMTHong Kong, 2025-12Share-based payments
10JD IndustrialsIndustrialHong Kong, 2025-12Financial assets
11BiocytogenPharmaceuticalsSSE STAR Market, 2025-12Biological assets
12Moore ThreadsTMTSSE STAR Market, 2025-12Shareholding restructuring; share-based payments; financial assets
13Jinyan Kaolin New MaterialsEnergyHong Kong, 2025-12Property valuation
14SERESAutomotiveHong Kong, 2025-11Expected credit losses; long-term equity investments; employee options
15SICCTMTHong Kong, 2025-08Property valuation
16YimutianTMTNasdaq, 2025-08Convertible bonds; employee options; equity valuation
17HEC PharmPharmaceuticalsHong Kong, 2025-08Property valuation
18Youlan InternationalEducationNasdaq, 2025-07Purchase price allocation; goodwill impairment testing; preferred shares
19UnisoundTMTHong Kong, 2025-06Employee options; preferred shares; long-term equity investments
20TransTheraPharmaceuticalsHong Kong, 2025-06Equity incentives; equity valuation; intangible assets
21Baize MedicalHealthcareHong Kong, 2025-06PPA; goodwill impairment testing
22Shouhui GroupTMTHong Kong, 2025-05Preferred shares; employee options
23MirxesMedical DevicesHong Kong, 2025-05Purchase price allocation; goodwill impairment testing
24Green TeaFood & BeverageHong Kong, 2025-05Valuation for tax reporting
25Auntea JennyConsumer GoodsHong Kong, 2025-05Employee options; incremental borrowing rate; long-term equity investments
26CHAGEEConsumer GoodsNasdaq, 2025-04Share-based payments; equity valuation
27New Gonow Recreational VehiclesAutomotiveHong Kong, 2025-01Share-based payments
28Biostar PharmaPharmaceuticalsHong Kong, 2024-10Property valuation
29Horizon RoboticsTMTHong Kong, 2024-10Preferred shares; convertible bonds; warrants; long-term equity investments
30BaiwangTMTHong Kong, 2024-06Warrants; purchase price allocation; preferred shares
31DidaTMTHong Kong, 2024-06Preferred shares; employee options; convertible bonds
32Easou TechnologyTMTHong Kong, 2024-06Preferred shares; employee options
33ZEEKRAutomotiveNYSE, 2024-05Preferred shares; restricted stock
34Qyuns TherapeuticsPharmaceuticalsHong Kong, 2024-03Preferred shares; options
35Concord HealthcareHealthcareHong Kong, 2024-01Impairment testing; expected credit losses; convertible bonds
36Lancang Ancient TeaConsumer GoodsHong Kong, 2023-12Inventory
37Shiyue DaotianConsumer GoodsHong Kong, 2023-10Financial liabilities
38ZX Inc.TMTHong Kong, 2023-09Purchase price allocation; share-based payments; impairment testing of long-term investments
39Tuhu CarTMTHong Kong, 2023-09Purchase price allocation; share-based payments; equity valuation
40ZJLD GroupConsumer GoodsHong Kong, 2023-04Equity value
41Kang Le Wei ShiPharmaceuticalsBeijing Stock Exchange, 2023-03Share-based payments; value testing
42FenbiEducationHong Kong, 2023-01Preferred shares; employee options
43Super Hi InternationalFood & BeverageHong Kong, 2022-12Asset disposals
44ECARXTMTNasdaq, 2022-12Share-based payments; warrants; equity valuation
45Gaush MeditechHealthcareHong Kong, 2022-12Purchase price allocation; convertible bonds; preferred shares; guarantee rights
46Flowing CloudTMTHong Kong, 2022-10Preferred shares; equity valuation
47BiocytogenBiopharmaceuticalsHong Kong, 2022-09Employee options; biological assets; enterprise value
48LongsysTMTShenzhen Stock Exchange, 2022-05Equity valuation
49RainmedHealthcare (Medical Devices)Hong Kong, 2022-07Preferred shares; employee options; enterprise value
50SANY Renewable EnergyWind PowerSSE STAR Market, 2022-06Purchase price allocation
51ZhihuTMTHong Kong, 2022-04Employee options; preferred shares
52UJU HoldingTMTHong Kong, 2021-11Employee options; enterprise valuation
53Acotec ScientificHealthcare (Medical Devices)Hong Kong, 2021-08Equity valuation; purchase price allocation; employee options; preferred shares
54Chaoju Eye CareHealthcare (Ophthalmology)Hong Kong, 2021-07Equity valuation; purchase price allocation; goodwill impairment testing; share-based payments
55JD LogisticsTMTHong Kong, 2021-05Equity valuation; purchase price allocation
56BairongTMTHong Kong, 2021-03Equity valuation; preferred equity valuation; employee options
57ZhihuTMTNYSE, 2021-03Preferred equity valuation; employee options
58First High-School EducationEducationNYSE, 2021-03Purchase price allocation; employee options; leased properties; goodwill impairment testing
59Cheerwin GroupConsumer GoodsHong Kong, 2021-03Enterprise valuation for tax purposes
60KuaishouTMTHong Kong, 2021-02-05Available-for-sale financial assets
61Kuke MusicTMTNYSE, 2021-01Preferred shares; share-based payments
62Jacobio PharmaceuticalsPharmaceuticalsHong Kong, 2020-12Equity valuation; preferred equity valuation; employee options
63Jinhui HoldingsReal EstateHong Kong, 2020-10Purchase price allocation; share-based payments
64First Service HoldingReal EstateHong Kong, 2020-10Purchase price allocation
65Zonbong LandscapeEngineeringHong Kong, 2021-01Purchase price allocation; biological assets; available-for-sale assets
66Newlink TechnologyTMTHong Kong, 2021-01Business valuation
67G.H.Y Culture & MediaFilm & MediaSingapore, 2020-12Expected credit loss assessment; purchase price allocation
68Farasis EnergyNew EnergySSE STAR Market, 2020-07Preferred shares; share-based payments
69Immunotech BiopharmPharmaceuticalsHong Kong, 2020-07Equity valuation; preferred equity valuation; employee options
70HepalinkPharmaceuticalsHong Kong, 2020-07Fund financial assets (equity valuation); purchase price allocation; convertible bonds; warrants; share-based payments
71BlueCityTMTNasdaq, 2020-07Purchase price allocation
72QuhuoTMTNasdaq, 2020-07Purchase price allocation; employee options; intangible assets
73Legend BiotechPharmaceuticalsNasdaq, 2020-06Allocation of licensing agreement value
74Hygeia HealthcareHealthcareHong Kong, 2020-06Preferred shares; purchase price allocation; restricted stock; goodwill impairment testing
75WiMi HologramTMTNasdaq, 2020-04Equity valuation
76AnPac BioBiomedicalNasdaq, 2020-01Share-based payments; purchase price allocation; asset impairment testing; equity valuation
77Lizhi FMTMTNasdaq, 2020-01Preferred shares; share-based payments; equity valuation
78Newborn TownTMTHong Kong, 2020-01Purchase price allocation; preferred shares; available-for-sale assets
79PharmaronBiomedicalHong Kong, 2019-11Property valuation
80China FeiheConsumer GoodsHong Kong, 2019-11Financial review and reconciliation
81CMGETMTHong Kong, 2019-10Fund financial assets (equity valuation); convertible bonds; contingent consideration; purchase price allocation; goodwill impairment testing
82Xinyuan PropertyProperty ManagementHong Kong, 2019-10Equity valuation; share-based payments; restricted stock; purchase price allocation; goodwill impairment testing
83EuroEyesHealthcare (Ophthalmology)Hong Kong, 2019-10Equity valuation; purchase price allocation; share-based payments
84JH EducationalEducationHong Kong, 2019-06Property valuation; purchase price allocation; goodwill impairment testing
85China Kepei EducationEducationHong Kong, 2019-01Property valuation; purchase price allocation; goodwill impairment testing; share-based payments
86InkeTMTHong Kong, 2018-07Purchase price allocation; goodwill impairment testing; financial assets; share-based payments
87China New Higher EducationEducationHong Kong, 2017-04Property valuation; purchase price allocation; goodwill impairment testing
88Yuhua EducationEducationHong Kong, 2017-03Property valuation; purchase price allocation; convertible bonds

Records are compiled from the company profile. Listing information and valuation scopes follow the source materials; separate listings for the same client are shown individually.

View Original